Interleukin-6 as an Early Chronic Inflammatory Marker in Polycystic Ovary Syndrome with Insulin Receptor Substrate-2 Polymorphism

Yue Shan Lin, Shaw Jenq Tsai, Ming Wei Lin, Cheng Ta Yang, Mei Feng Huang, Meng Hsing Wu

Research output: Contribution to journalArticle

21 Citations (Scopus)


Problem Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder. This study was to evaluate whether insulin receptor substrate (IRS)-2 Gly1057Asp polymorphism influences chronic inflammatory parameters in Taiwanese patients with PCOS. Method of study DNA was extracted from whole blood samples for genotyping and detection of IRS-2 Gly1057Asp polymorphism in 129 PCOS women and 109 control women. Ninety-seven PCOS women accepted metformin treatment for 3months, and low-grade chronic inflammatory markers were assessed. Results The levels of IL-6 were significantly elevated in PCOS women compared with normal women. Among allelic variant of IRS-2, concentrations of IL-6 were greater in IRS-2 homozygous Asp population. Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant. Conclusion The results showed that IL-6 may be an early low-grade chronic inflammatory marker among PCOS patients with IRS-2 polymorphism in Taiwanese population. This pharmacologic study in IRS-2 polymorphism may provide more information for preventing long-term complications in PCOS.

Original languageEnglish
Pages (from-to)527-533
Number of pages7
JournalAmerican Journal of Reproductive Immunology
Issue number6
Publication statusPublished - Dec 2011



  • Chronic inflammatory marker
  • Insulin receptor substrate-2
  • Interleukin-6
  • Metformin
  • Polycystic ovary syndrome
  • Polymorphism

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this